Table 2 Characteristics of cohort studies
Author, Year | Country | Size of cohort (M/F) | PD cases (M/F) | Age at baseline (Y) | Study period (starting-ending year) | Assessment of PD | Assessment of status of S-C and S-TG |
|---|---|---|---|---|---|---|---|
Simon 2010 [29] | USA | 171,879 (50,833/121046) | 530 (NA) | 30–75 | 22.9 (1976–2000) | Parkinsonian signs | Self reported |
Huang 2008 [30] | USA | 3223 (3223/0) | 41 (41/0) | 71–79 | 3 (1991–1993) | Medical records & neurologic examination | Laboratories records |
Benn 2017 [31] | Danish | 111,194 (49,884/61310) | 460 (NA) | 46–66 | 39 (1976–2014) | Medical records | Laboratories records |
Saaksjarvi 2015 [32] | Finland | 6641 (3102/3539) | 89 (49/40) | 30–79 | 30 (1978–2007) | Datebase | Laboratories records |
de Lau 2006 [9] | Netherlands | 6465 (2654/3811) | 87 (46/41) | ≥55 | 9.4 (1990–2004) | Parkinsonian signs & neurologic examination | Laboratories records |
Hu 2008 [33] | Finland | 50,926 (24,773/26153) | 625 (321/304) | 25–64 | 18.1 (1972–1997) | Medical records & neurologic examination | Laboratories records |
Grandnetti 1994 [34] | USA | 8006 (8006/0) | 58 (NA) | 71–93 | 26 (1965–1991) | Medical records | Laboratories records |
Fang 2019 [35] | Sweden | 610,141 (313,044/297097) | 3769 (NA) | 15–77 | 26 (1985–2011) | Medical records | Laboratories records |